Treximet (sumatriptan/naproxen sodium) is currently under the protection of patents that prevent drug companies from manufacturing any generic Treximet products. As soon as the first patent expires, which could be as soon as August 2017, other companies may begin producing a generic version of this medication.
Treximet™ (sumatriptan/naproxen sodium) is a prescription medication approved to treat migraines. Although it is effective for treating a migraine once it starts, Treximet cannot be used to prevent migraines.
Treximet is made by GlaxoSmithKline. Because the patents for Treximet have not expired, there are no generic versions of Treximet currently available.
The first patent for Treximet is set to expire in August 2017. This is the earliest predictable date that a generic version of Treximet could become available. However, there are other circumstances that could come up to extend or shorten the exclusivity period of Treximet. This could include such things as lawsuits or patents for other Treximet uses. Once Treximet goes off patent, there may be several companies that will begin manufacturing a generic version of the drug.
Imitrex® contains just sumatriptan, while Treximet contains both sumatriptan and naproxen sodium. Since naproxen is readily available (with or without a prescription) and is inexpensive, some people may choose to take Imitrex plus naproxen instead of Treximet, especially if Treximet is not covered by their insurance. However, if your insurance covers Treximet, it may actually be less expensive (and more convenient) for you to take Treximet. This will depend on the details of your particular insurance plan.